查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1988191

腦和脊髓癌市場：2026-2032年全球市場預測（按癌症類型、治療方法、患者年齡層、最終用戶和分銷管道分類）

Brain & Spinal Cord Cancer Market by Cancer Type, Treatment Type, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年腦部和脊髓癌市場價值為 42.1 億美元，預計到 2026 年將成長至 44.6 億美元，複合年成長率為 5.98%，到 2032 年將達到 63.3 億美元。

主要市場統計數據
基準年 2025 42.1億美元
預計年份：2026年 44.6億美元
預測年份 2032 63.3億美元
複合年成長率 (%) 5.98%

策略性地實施臨床、監管和營運因素的整合，這些因素正在重塑神經腫瘤學的診斷、治療和護理服務。

本執行摘要概述了影響腦部和脊髓腫瘤診療的最關鍵的臨床、營運和策略主題。分子特徵分析和精準醫學的進步重新定義了診斷流程，同時也增加了治療決策的複雜性。同時，不斷發展的醫療服務模式以及多學科協作日益重要的作用，正在改變患者在診斷、治療和復原過程中的體驗。

對正在重新定義神經腫瘤治療模式和相關人員期望的變革性科學、醫療保健服務和政策轉變進行清晰的檢驗。

治療創新是推動改變的最主要動力，標靶治療、免疫療法和先進的放射療法正在改變傳統的治療流程治療方法。精準診斷能夠將患者按分子特徵進行分類，從而製定更個人化的治療計劃，同時也需要整合生物標記檢測基礎設施和建立新的診療路徑。這些科學進步與技術和醫療設備的改進相輔相成，例如更安全的手術技術和更精準的立體定位放射治療系統，這些共同作用降低了併發症率，並擴大了符合治療條件的患者群體。

對 2025 年美國關稅政策變化將如何重塑神經腫瘤治療方法和醫療設備的供應鏈、籌資策略和准入動態進行深入分析。

美國2025年實施的關稅政策，為腦癌和脊髓癌治療治療方法及醫療設備的採購、生產和全球籌資策略帶來了新的考量。活性成分、醫療設備及相關耗材的關稅調整影響了成本結構，促使各機構重新評估供應商多元化和近岸外包方案。這些政策變化使企業更加關注總到岸成本，並激勵獎勵建立本地製造夥伴關係和加強合約保護。

高解析度分割分析揭示了腫瘤類型、治療方法、患者年齡層、醫療保健環境和分銷管道如何共同決定臨床和商業性優先事項。

基於細分市場的分析揭示了腫瘤生物學特徵、治療方法、年齡層、醫療機構和分銷管道等方面的細微需求模式和策略重點。按癌症類型分類，市場分析涵蓋星狀細胞瘤、室管膜瘤、膠質母細胞瘤、髓母細胞瘤、腦膜瘤、少突膠質細胞瘤和神經鞘瘤，每種癌症都具有獨特的臨床病程、生物標記特徵和影響治療方法選擇的手術考量。按治療方法分類，涵蓋化療、免疫療法、放射線治療、支持性治療、手術和標靶治療，其中化療進一步細分為烷化劑、亞硝基脲類藥物和含鉑類藥物。免疫療法分為CAR-T細胞療法和查核點抑制劑，放射線治療分為體外放射治療、質子治療和立體定位放射放射線手術。手術分為開顱手術、雷射消熔和微創切除術。標靶治療的特點是使用激酶抑制劑和單株抗體。

區域分析整合了美洲、歐洲、中東和非洲以及亞太地區的臨床能力、監管複雜性和准入因素，有助於制定優先策略。

區域趨勢對腦和脊髓腫瘤的臨床能力、法規環境以及先進治療的機會有顯著影響。在美洲，綜合性學術中心和專科癌症網路往往能夠推動新型外科技術和先進放射治療方法的早期應用，而與保險公司的談判和報銷政策則影響著商業性應用的速度。區域內的跨國合作有助於參與臨床試驗和知識交流，但都市區三級醫療機構與區域醫療服務提供者之間仍然存在資源獲取方面的差距，這影響著複雜醫療服務的公平性。

競爭考察，重點關注神經腫瘤學領域市場領導的創新組合、策略夥伴關係和實證商業化方法。

神經腫瘤領域的主要企業正透過標靶治療、先進放射治療平台和支持性護理解決方案的綜合產品組合來脫穎而出。它們的策略行動呈現出幾個顯著的模式，包括投資精準診斷以確保患者篩選的準確性，與學術機構合作以加速轉化研究和臨床試驗的開展，以及透過許可協議擴大地域覆蓋範圍並降低研發風險。此外，各企業也積極推動特種化合物和無菌注射劑供應鏈的垂直整合，以降低供應中斷的風險。

為神經腫瘤護理路徑領域的行業領導者提供切實可行的優先建議，以加快治療效果、加強供應鏈並擴大公平獲取途徑。

產業領導者應採取平衡的短期和長期措施，以應對臨床影響、供應鏈韌性和公平取得等問題。優先投資生物標記項目和綜合診斷，以確保準確篩選患者並最大限度地提高治療效果。除了分子策略外，還應建立完善的註冊登記系統和真實世界數據（REW）項目，以收集神經認知結果和長期生活品質（QOL）指標。這些指標在醫保報銷討論和臨床醫生採納方面正發揮著越來越重要的作用。

採用透明、嚴謹的混合方法研究途徑，結合文獻整合、專家訪談和證據三角檢驗，以支持策略性結論並找出限制。

本分析採用混合方法研究設計，結合系統性的二手資料研究和針對性的原始研究，以驗證檢驗並彌補證據缺口。二手資料包括同儕審查文獻、臨床試驗註冊資訊、監管文件和政策公告，從而全面了解治療機制、臨床終點和監管先例。文獻整合優先考慮高品質的隨機對照試驗、關鍵醫療設備的評估以及共識指南的更新，為基於最有力證據的臨床解讀提供支援。

明確整合，強調臨床創新、營運韌性和協調政策行動的相互依存的優先事項，這對於改善神經腫瘤學的治療效果至關重要。

科學創新、不斷發展的醫療服務模式和不斷變化的政策相互交匯，要求整個神經腫瘤生態系統做出協調一致的回應。儘管先進的診斷技術和新型治療方法為提高生存率和保護神經功能帶來了真正的希望，但要實現這一目標，需要強力的循證策略、穩健的供應鏈和公平的醫療服務獲取機制。因此，相關人員必須儘早與保險公司展開對話，使臨床研發與真實世界數據（REW）的收集相契合，並從病患和醫療系統的角度清晰地展現其價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按癌症類型分類的腦部和脊髓癌市場

  • 星狀細胞瘤
  • 室管膜瘤
  • 膠質母細胞瘤
  • 髓母細胞瘤
  • 腦膜瘤
  • 少突膠質細胞瘤
  • 雪旺細胞瘤

第9章：依治療方法分類的腦部和脊髓癌市場

  • 化療
    • 烷化劑
    • 亞硝基脲類藥物
    • 含鉑類藥物
  • 免疫療法
    • CAR-T細胞療法
    • 查核點抑制劑
  • 放射線治療
    • 外部輻射
    • 質子束療法
    • 立體定位放射放射線手術
  • 支持性護理
  • 外科手術
    • 開顱手術
    • 雷射消熔
    • 微創切除術
  • 標靶治療
    • 激酶抑制劑
    • 單株抗體

第10章：依患者年齡層分類的腦部和脊髓癌市場

  • 成人版
  • 老年人
  • 兒童

第11章：腦和脊髓癌市場：依最終用戶分類

  • 門診手術中心
  • 癌症診所
  • 居家照護設施
  • 醫院

第12章：腦和脊髓癌市場：依通路分類

  • 診所藥房
  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專賣店

第13章：腦和脊髓癌市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 腦和脊髓癌市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 腦和脊髓癌市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國腦癌與脊髓癌市場

第17章：中國腦脊髓癌市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • bluebird bio, Inc.
  • Bristol Myers Squibb Company
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eisai Inc.
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc.
  • Nektar Therapeutics
  • Novartis AG
  • Novocure Limited
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Shimadzu Corporation
  • Siemens Healthineers
  • Teva Pharmaceutical Industries Ltd.
  • Y-mAbs Therapeutics A/S
Product Code: MRR-9E71DF483B96

The Brain & Spinal Cord Cancer Market was valued at USD 4.21 billion in 2025 and is projected to grow to USD 4.46 billion in 2026, with a CAGR of 5.98%, reaching USD 6.33 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.21 billion
Estimated Year [2026] USD 4.46 billion
Forecast Year [2032] USD 6.33 billion
CAGR (%) 5.98%

A strategic introduction to the converging clinical, regulatory, and operational forces that are reshaping diagnosis, treatment, and care delivery in neuro-oncology

This executive summary distills the most consequential clinical, operational, and strategic themes shaping care for brain and spinal cord cancers. Advances in molecular characterization and precision therapeutics have redefined diagnostic pathways while concurrently introducing new complexity into treatment decision-making. At the same time, evolving care-delivery models and greater emphasis on multidisciplinary coordination are shifting how patients experience diagnosis, treatment, and survivorship.

Regulatory pathways are evolving in parallel, with accelerated approvals and adaptive trial designs enabling earlier patient access to novel interventions. These innovations come with heightened requirements for real-world evidence and post-approval data that stakeholders must integrate into lifecycle planning. Equally important are the system-level forces-supply chain fragility, workforce constraints, and payment policy debates-that influence how innovations translate into practice.

Taken together, these dynamics create both opportunity and responsibility for commercial teams, clinical leaders, and payers. This summary presents a structured view of the transformational shifts, tariff-driven supply considerations, segmentation-driven insights, regional distinctions, and competitive behaviors that should inform strategy and investment priorities across the neuro-oncology ecosystem.

A clear-eyed review of the transformative scientific, care-delivery, and policy shifts that are redefining neuro-oncology treatment paradigms and stakeholder expectations

Therapeutic innovation is the most visible driver of change, with targeted agents, immunotherapies, and advanced radiation modalities altering conventional treatment algorithms. Precision diagnostics now stratify patients into molecularly defined cohorts, enabling more personalized regimens but also requiring integrated biomarker testing infrastructure and new care pathways. These scientific advances are complemented by procedural and device improvements, including safer surgical techniques and more precise stereotactic delivery systems, which together reduce morbidity and expand treatment candidacy.

Care delivery is undergoing a parallel transformation. Multidisciplinary tumor boards, virtual care modalities, and decentralized treatment options are increasing access while challenging traditional hospital-centric models. Payers and health systems are experimenting with value-based frameworks and outcomes-based contracting, which emphasize real-world outcomes over traditional procedural volumes. These shifts force manufacturers and providers to demonstrate sustained clinical benefit, manage total cost of care, and invest in longitudinal evidence generation.

Finally, patient expectations and advocacy voices now play a central role in shaping research priorities and regulatory conversations. Patients seek therapies that not only extend survival but preserve neurologic function and quality of life, prompting greater attention to neurocognitive endpoints and supportive care integration. As a result, stakeholders must navigate a more complex, patient-centered landscape that demands agility, cross-sector partnerships, and robust evidence strategies.

An incisive assessment of how United States tariff policy changes in 2025 are reshaping supply chains, sourcing strategies, and access dynamics for neuro-oncology therapies and devices

United States tariff policies enacted in 2025 have introduced new considerations across procurement, manufacturing, and global sourcing strategies for therapies and devices used in brain and spinal cord cancer care. Tariff adjustments on active pharmaceutical ingredients, medical devices, and ancillary supplies affect cost structures and have prompted organizations to reassess supplier diversification and nearshoring options. These policy changes heightened attention to total landed cost and created incentives for local manufacturing partnerships and contractual protections.

Supply chain disruption risk has increased the premium on inventory visibility, multi-sourcing strategies, and strategic stockpiles for critical items such as specialty oncology drugs, implantable devices, and precision radiation components. Manufacturers are responding by redesigning logistics networks, qualifying alternate suppliers, and revising pricing contracts to reflect increased import costs and mitigation investments. Procurement teams and finance leaders are now more actively engaging in scenario planning to quantify tariff-related operational impacts and ensure continuity of patient care.

Regulatory and commercial teams must also account for potential downstream effects on access and reimbursement. Payers may adjust formulary strategies or reimbursement rates in response to higher acquisition costs, while providers could face pressure on margins that affects adoption of newer, higher-cost modalities. Therefore, organizations should prioritize transparent supplier relationships, advocate for policy mechanisms that protect patient access, and develop evidence-based value propositions that reconcile higher unit costs with clinical and economic outcomes.

High-resolution segmentation insights revealing how tumor types, therapeutic modalities, patient age cohorts, care settings, and distribution channels jointly determine clinical and commercial priorities

Segmentation-driven analysis reveals nuanced demand patterns and strategic priorities across tumor biology, therapeutic modality, age demographics, care settings, and distribution channels. Based on Cancer Type, market analysis covers Astrocytoma, Ependymoma, Glioblastoma, Medulloblastoma, Meningioma, Oligodendroglioma, and Schwannoma, each presenting distinct clinical courses, biomarker profiles, and surgical considerations that inform therapeutic choices. Based on Treatment Type, the landscape spans Chemotherapy, Immunotherapy, Radiation Therapy, Supportive Care, Surgery, and Targeted Therapy, with chemotherapy further detailed into Alkylating Agents, Nitrosoureas, and Platinum Based Agents; immunotherapy delineated into CAR T Cell Therapy and Checkpoint Inhibitors; radiation therapy separated into External Beam Radiation, Proton Therapy, and Stereotactic Radiosurgery; surgery differentiated by Craniotomy, Laser Ablation, and Minimally Invasive Resection; and targeted therapy characterized by Kinase Inhibitors and Monoclonal Antibodies.

Patient demographics materially influence clinical and commercial approaches. Based on Patient Age Group, the analysis distinguishes Adult, Geriatric, and Pediatric populations, capturing differences in tumor biology, tolerability, and long-term survivorship needs that drive distinct evidence requirements and service models. Based on End User, care delivery is examined across Ambulatory Surgical Centers, Cancer Clinics, Home Care Settings, and Hospitals, reflecting varied capabilities for delivering complex interventions, managing complications, and coordinating multidisciplinary care. Based on Distribution Channel, the study assesses Clinic Pharmacies, Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Specialty Stores, recognizing that channel choice affects adherence, specialty drug handling, and patient support programs.

Integrating these segmentation lenses highlights intersections that organizations must prioritize: for example, how geriatric presentations of specific tumor types alter suitability for aggressive surgery or systemic therapy; how pediatric tumor biology drives enrollment in specialized trials; how selection of radiation modality depends on tumor location and patient age; and how distribution channel strategies can either enable or constrain adherence and home-based supportive care programs. These insights support targeted product development, evidence generation, and commercial models that align with the heterogeneous needs across neuro-oncology care pathways.

Regional intelligence synthesizing clinical capacity, regulatory complexity, and access drivers across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform prioritized strategies

Regional dynamics materially influence clinical capacity, regulatory environments, and access to advanced therapies for brain and spinal cord cancers. In the Americas, integrated academic centers and specialized cancer networks often drive early adoption of novel surgical techniques and advanced radiation modalities, while payer negotiations and reimbursement policy shape the pace of commercial uptake. Cross-border collaboration within the region supports clinical trial enrollment and knowledge exchange, but disparities in access persist between urban tertiary centers and community providers, which affects equitable delivery of complex care.

In Europe, Middle East & Africa, regulatory harmonization and regional procurement mechanisms coexist with widely varying health system capacities. High-resource European markets exhibit strong capabilities for precision diagnostics and proton therapy infrastructure, whereas parts of the Middle East and Africa emphasize capacity building, workforce development, and access to essential therapies. Strategic partnerships, technology transfer, and capacity-strengthening initiatives are therefore central to expanding access in these markets. Reimbursement frameworks and national policy priorities influence long-term adoption and the sustainability of advanced modalities.

In the Asia-Pacific region, rapid investments in oncology infrastructure and a growing emphasis on domestic biotech innovation are accelerating availability of targeted agents and advanced radiation services. However, heterogeneous payer systems and regulatory pathways create varying commercial entry considerations. In many jurisdictions, manufacturers must navigate complex local reimbursement criteria, pricing negotiations, and public-private partnerships to achieve broad access. Across regions, stakeholders should tailor evidence generation, access strategies, and manufacturing decisions to reflect local regulatory expectations, clinical practice norms, and infrastructure realities.

Competitive company insights emphasizing innovation portfolios, strategic partnerships, and evidence-driven commercialization approaches that differentiate market leaders in neuro-oncology

Leading companies in the neuro-oncology space are differentiating through integrated portfolios that combine targeted agents, advanced radiation platforms, and supportive care solutions. Strategic behaviors fall into several observable patterns: investment in precision diagnostics to ensure appropriate patient selection; partnerships with academic centers to accelerate translational research and trial enrollment; and licensing agreements that expand geographic reach while mitigating development risk. Firms are also pursuing vertical integration in supply chains for specialty compounds and sterile injectable formulations to reduce disruption risk.

Collaboration models are evolving from simple co-development agreements to multifaceted alliances that include data-sharing frameworks, joint real-world evidence initiatives, and outcomes-based contracting pilots. These arrangements allow organizations to align reimbursement with demonstrated patient benefit and to share both clinical and financial risk. From a commercialization perspective, companies are placing greater emphasis on patient support services, digital engagement tools to improve adherence, and hub-and-spoke distribution models that accommodate the handling needs of complex biologics and cell therapies.

Competitive differentiation increasingly depends on demonstrating long-term neurologic outcomes and value across care episodes rather than single-point efficacy. As a result, corporate strategies that integrate robust evidence generation, adaptive pricing models, and strategic partnerships with provider networks will be better positioned to capture sustained uptake while addressing payer and patient expectations.

Practical and prioritized recommendations for industry leaders to accelerate therapeutic impact, fortify supply chains, and expand equitable access within neuro-oncology care pathways

Industry leaders should pursue a balanced set of near-term and long-term actions that address clinical impact, supply chain resilience, and equitable access. Prioritize investment in biomarker programs and integrated diagnostics to ensure precise patient selection and to maximize therapeutic benefit. Complement molecular strategies with robust registries and real-world evidence programs that capture neurocognitive outcomes and longitudinal quality-of-life measures, which are increasingly central to reimbursement discussions and clinician adoption.

Strengthen supply chains through diversification, qualification of alternate suppliers, and consideration of regional manufacturing partnerships to mitigate tariff and import risks. Build contractual flexibility and inventory visibility into procurement practices to reduce the operational strain of policy shifts. On the commercial front, design patient support models that align with distinct distribution channels and care settings, ensuring that specialty handling, adherence programs, and remote monitoring are embedded within the ambulatory and home-care contexts where appropriate.

Finally, cultivate collaborative ecosystems across industry, providers, and patient advocacy groups to accelerate trial enrollment, align evidence priorities, and advocate for policies that preserve access to high-value interventions. Implementing these steps in concert will enable organizations to convert scientific advances into durable clinical improvements and sustainable commercial outcomes.

A transparent and rigorous mixed-methods research approach that combines literature synthesis, expert interviews, and evidence triangulation to underpin strategic conclusions and acknowledge limitations

The analysis integrates a mixed-methods research design that pairs systematic secondary research with targeted primary engagements to validate findings and fill evidence gaps. Secondary sources included peer-reviewed literature, clinical trial registries, regulatory documents, and policy releases to construct a comprehensive view of therapeutic mechanisms, clinical endpoints, and regulatory precedents. This literature synthesis prioritized high-quality randomized trials, pivotal device evaluations, and consensus guideline updates to ground clinical interpretations in the strongest available evidence.

Primary research comprised interviews with clinical experts, health system leaders, payer representatives, and supply chain professionals to elicit perspectives on adoption barriers, reimbursement dynamics, and operational resilience. Expert input informed scenario planning around tariff impacts, procurement responses, and regional capacity constraints. Evidence synthesis applied thematic coding to reconcile divergent viewpoints and to surface priority areas for strategic action, while sensitivity assessments highlighted dependencies and potential limitations.

Limitations of the methodology include the evolving nature of regulatory decisions and rapidly emerging clinical data that may alter practice patterns. To mitigate these constraints, the study emphasizes transparent assumptions, documents data vintage for key inputs, and identifies areas where ongoing surveillance and periodic updates will be necessary to maintain strategic relevance.

A conclusive synthesis that emphasizes the interdependent priorities of clinical innovation, operational resilience, and collaborative policy action necessary to improve neuro-oncology outcomes

The convergent forces of scientific innovation, evolving care delivery, and shifting policy require coordinated responses across the neuro-oncology ecosystem. Precision diagnostics and novel therapeutics offer genuine promise for improving survival and preserving neurologic function, yet realizing that promise depends on robust evidence strategies, resilient supply chains, and equitable access frameworks. Stakeholders must therefore align clinical development with real-world evidence generation and engage payers early to articulate value in terms that matter to patients and health systems.

Operationally, organizations should focus on supply chain diversification, strategic manufacturing partnerships, and procurement practices that absorb policy shocks while protecting patient continuity of care. Region-specific strategies will be necessary to reflect heterogeneity in regulatory pathways, infrastructure, and reimbursement models. Commercial success will increasingly hinge on integrated offers that combine therapeutics with diagnostics, patient support services, and digital tools that facilitate adherence and outcome measurement.

In summary, transforming advances into durable improvements requires a systems-level perspective that balances innovation with practical implementation. By prioritizing evidence generation, operational resilience, and collaborative engagement, stakeholders can accelerate meaningful improvements in outcomes for people affected by brain and spinal cord cancers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain & Spinal Cord Cancer Market, by Cancer Type

  • 8.1. Astrocytoma
  • 8.2. Ependymoma
  • 8.3. Glioblastoma
  • 8.4. Medulloblastoma
  • 8.5. Meningioma
  • 8.6. Oligodendroglioma
  • 8.7. Schwannoma

9. Brain & Spinal Cord Cancer Market, by Treatment Type

  • 9.1. Chemotherapy
    • 9.1.1. Alkylating Agents
    • 9.1.2. Nitrosoureas
    • 9.1.3. Platinum Based Agents
  • 9.2. Immunotherapy
    • 9.2.1. CAR T Cell Therapy
    • 9.2.2. Checkpoint Inhibitors
  • 9.3. Radiation Therapy
    • 9.3.1. External Beam Radiation
    • 9.3.2. Proton Therapy
    • 9.3.3. Stereotactic Radiosurgery
  • 9.4. Supportive Care
  • 9.5. Surgery
    • 9.5.1. Craniotomy
    • 9.5.2. Laser Ablation
    • 9.5.3. Minimally Invasive Resection
  • 9.6. Targeted Therapy
    • 9.6.1. Kinase Inhibitors
    • 9.6.2. Monoclonal Antibodies

10. Brain & Spinal Cord Cancer Market, by Patient Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Brain & Spinal Cord Cancer Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cancer Clinics
  • 11.3. Home Care Settings
  • 11.4. Hospitals

12. Brain & Spinal Cord Cancer Market, by Distribution Channel

  • 12.1. Clinic Pharmacies
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies
  • 12.5. Specialty Stores

13. Brain & Spinal Cord Cancer Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Brain & Spinal Cord Cancer Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brain & Spinal Cord Cancer Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Brain & Spinal Cord Cancer Market

17. China Brain & Spinal Cord Cancer Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Bayer AG
  • 18.9. bluebird bio, Inc.
  • 18.10. Bristol Myers Squibb Company
  • 18.11. Dr. Reddy's Laboratories Ltd.
  • 18.12. Eisai Co., Ltd.
  • 18.13. Eisai Inc.
  • 18.14. F. Hoffmann-La Roche Ltd
  • 18.15. Genentech, Inc.
  • 18.16. GlaxoSmithKline PLC
  • 18.17. Illumina, Inc.
  • 18.18. Johnson & Johnson Services, Inc
  • 18.19. Merck & Co., Inc.
  • 18.20. Nektar Therapeutics
  • 18.21. Novartis AG
  • 18.22. Novocure Limited
  • 18.23. Pfizer Inc.
  • 18.24. Regeneron Pharmaceuticals, Inc.
  • 18.25. Shimadzu Corporation
  • 18.26. Siemens Healthineers
  • 18.27. Teva Pharmaceutical Industries Ltd.
  • 18.28. Y-mAbs Therapeutics A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRAIN & SPINAL CORD CANCER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SCHWANNOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SCHWANNOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SCHWANNOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NITROSOUREAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NITROSOUREAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NITROSOUREAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PROTON THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PROTON THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PROTON THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LASER ABLATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LASER ABLATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LASER ABLATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MINIMALLY INVASIVE RESECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MINIMALLY INVASIVE RESECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MINIMALLY INVASIVE RESECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINIC PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINIC PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINIC PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SPECIALTY STORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SPECIALTY STORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SPECIALTY STORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 234. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 265. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 267. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 272. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 275. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 278. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 280. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)